Targeting MMP-12 to treat diseases that have no good answers
Primevera Therapeutics is advancing a focused portfolio of MMP-12 inhibitors across pulmonary, cardiac, gastrointestinal, and neurologic indications, with programs spanning clinical and preclinical development.
MMP-12 Inhibitors for Inflammatory and Fibrotic Diseases
Primevera Therapeutics is a clinical-stage biotechnology company developing selective MMP-12 inhibitors to treat diseases driven by chronic inflammation, tissue remodeling, and fibrosis, including sarcoidosis, asthma, COPD, inflammatory bowel disease, interstitial lung diseases, and neurologic disorders.
Understanding the MMP-12 Opportunity
What Is MMP-12?
Matrix metalloproteinase-12 (MMP-12) is a macrophage-derived enzyme that contributes to:
- chronic inflammatory signaling
- extracellular matrix degradation
- progressive tissue damage and fibrosis
Elevated MMP-12 activity has been implicated in pulmonary, cardiac, gastrointestinal, and neurologic diseases, making it a validated therapeutic target.
How MMP-12 Inhibitors Work
Selective MMP-12 inhibitors are designed to:
- reduce macrophage-driven inflammation
- limit extracellular matrix breakdown
- slow disease-associated tissue remodeling
Unlike earlier non-selective metalloproteinase inhibitors, selective MMP-12 inhibition aims to preserve safety while addressing upstream disease biology.
Why Target MMP-12?
MMP-12 is associated with:
- macrophage activation
- chronic inflammatory cascades
- extracellular matrix degradation
- fibrosis and loss of organ function
Targeting MMP-12 offers a mechanism-based approach to treating inflammatory and fibrotic diseases rather than symptom management alone.
Therapeutic Compounds in Development
| Compound | Indications | Description |
|---|---|---|
|
Linvemastat
FP-020
|
Linvemastat (FP-020) is a selective MMP-12 inhibitor targeting inflammatory pathways common to asthma, COPD, and inflammatory bowel disease, conditions characterized by macrophage-mediated tissue injury. |
|
|
Aderamastat
FP-025
|
Aderamastat (FP-025) is a clinically advanced MMP-12 inhibitor being developed for sarcoidosis, including cardiac sarcoidosis, where chronic inflammation and fibrosis contribute to organ dysfunction. |
|
|
Next-Gen MMP-12
Inhibitors
|
A new series of MMP-12 inhibitors is in preclinical development for interstitial lung diseases and neurologic disorders, where inflammation-driven tissue remodeling contributes to progressive disease. |
Frequently asked questions
What diseases are MMP-12 inhibitors used for?
MMP-12 inhibitors are being developed for inflammatory and fibrotic diseases including sarcoidosis, asthma, COPD, inflammatory bowel disease, interstitial lung diseases, and neurologic disorders.
Are MMP-12 inhibitors selective?
Modern MMP-12 inhibitors are designed to selectively inhibit MMP-12, reducing off-target effects seen with earlier broad-spectrum metalloproteinase inhibitors.
Let's connect
We welcome inquiries from investors, research partners, and collaborators interested in our MMP-12 platform.